摘要:
It is provided that a pharmaceutical composition inhibiting cartilage extracellular matrix degradation containing a compound of the formula (I): wherein R1 is hydroxy and the like; R2 is optionally substituted lower alkyl and the like; R3 is hydrogen atom and the like; R4 is optionally substituted arylene and the like; R5 is a bond, or —C≡C— and the like; R6 is optionally substituted aryl and the like, its optically active substance, its prodrug, their pharmaceutically acceptable salt, or solvate thereof.
摘要翻译:提供了抑制软骨细胞外基质降解的药物组合物,其含有式(I)化合物:其中R 1是羟基等; R 2是任意取代的低级烷基等; R 3是氢原子等; R 4是任选取代的亚芳基等; R 5是键,或-C≡C-等; R 6是任选取代的芳基等,其光学活性物质,其前药,其药学上可接受的盐或溶剂化物。
摘要:
A compound represented by the general formula (I-A): wherein R1 is hydroxy and the like; R2 is optionally substituted lower alkyl and the like; R3 is hydrogen atom and the like; R4 is optionally substituted arylene and the like; R5 is a group represented by the formula: R6 is optionally substituted aryl and the like, its optically active substance, their pharmaceutically acceptable salt, or a solvate thereof; and a metalloproteinase inhibitor containing them.
摘要:
Since it is thought that if the activity of MMP-13 can be inhibited, this will largely contribute to improvement or prevention of progession of pathological states, particularly, osteoarthritis (OA), resulting from or associated with the MMP-13 activity, the development of MMP-13 inhibitors is anticipated. There are provided a compound represented by the general formula (I): wherein R1 is optionally substituted aryl etc.; Z is C1-C5 alkylene which may be substituted and may be interrupted with a substituent selected from Substituent group a etc.; A is the formula: (R6 and R7 are each independently halogen, lower alkyl etc.; m and n are each independently 0, 1, or 2); R2 is a hydrogen atom, optionally substituted lower alkyl etc.; R3 is a hydrogen atom, optionally substituted lower alkyl etc.; R4 is a hydrogen atom; or R3 and R4 may be taken together with an adjacent carbon atom to from a ring; R5 is hydroxy, lower alkyloxy etc.), or an optically active isomer, a pharmaceutically acceptable salt or a solvate thereof, and a pharmaceutical composition containing it as an active ingredient, which has the MMP-13 inhibiting activity.
摘要:
An ink jet recording apparatus includes a full-line type recording head having plural ejection outlets; a shaft for rotatably supporting the recording head between a recording position in which the ink is ejected in a non-vertical direction and a non-recording position in which the ink is ejected substantially vertically; a device, disposed adjacent a recording position of the recording head, contributable to feeding of the recording material; and a positioning plate press-contacted to the contributable device to confine a recording surface of the recording material in cooperation with the contributable device.
摘要:
A process for preparing a compound of Formula (I): ##STR1## wherein R is phenyl or phenyl substituted with hydroxy, lower alkoxy, halogen or lower alkyl; Y is unsubstituted or substituted methylene, ethylene, vinylene or oxygen; m is 0 or 1; n is 0, 1 or 2; and q is 1, 2, 3 or 4; with the limitation that when m is 0, n is not 0, and when m is 1, n is not 2, which process comprises:(a) reacting an aldehyde of Formula (II); ##STR2## wherein R, Y, m and n are as defined above, under reaction conditions for the Wittig Reaction with a ylide of Formula (III):(R.sup.1).sub.3 P.dbd.CH(CH.sub.2).sub.q COOM (III) wherein R.sup.1 is C.sub.1 -C.sub.8 alkyl or aryl, M is an alkali metal and q is as defined above;(b) treating the reaction mixture of step (a) with an alkaline earth metal halide under alkaline conditions to form the alkaline earth metal salt of the carboxylic acid of Formula (I);(c) extracting the alkaline earth metal salt of the carboxylic acid of Formula (I) in an organic solvent; and(d) recovering the free carboxylic acid of Formula (I) from the organic solvent.
摘要:
A 7.beta.-ureidoacetamido-7.alpha.-methoxy-3-(1-carbamoylmethyl-1H-tetrazol-5-yl)thiomethyl-1-dethia-1-oxa-3-cephem-4-carboxylic acid derivative represented by the following formula: ##STR1## wherein Ar is phenyl, hydroxyphenyl, or thienyl and R is hydrogen, a light metal, or a carboxy-protecting group.
摘要:
A compound represented by the general formula (I-A): wherein R1 is hydroxy and the like; R2 is optionally substituted lower alkyl and the like; R3 is hydrogen atom and the like; R4 is optionally substituted arylene and the like; R5 is a group represented by the formula: R6 is optionally substituted aryl and the like, its optically active substance, their pharmaceutically acceptable salt, or a solvate thereof; and a metalloproteinase inhibitor containing them.
摘要翻译:由通式(I-A)表示的化合物:其中R 1是羟基等; R 2是任选取代的低级烷基等; R 3是氢原子等; R 4是任选取代的亚芳基等; R 5是由下式表示的基团:R 6是任选取代的芳基等,其光学活性物质,其药学上可接受的盐或其溶剂化物; 和含有它们的金属蛋白酶抑制剂。
摘要:
A composition for treating or preventing glomerulopathy which contains a compound of the formula (I): wherein, for example, R1 and R2 are each independently hydrogen atom, optionally substituted lower alkyl, optionally substituted aralkyl, etc.; R3 is 1,4-phenylene and 2,5-thiophendiyl; R4 is the substituents represented by the formula, etc.: wherein R6 is hydrogen atom, optionally substituted amino, etc.; and Y is NHOH or OH, its optically active substance, their pharmaceutically acceptable salt, or hydrate thereof.
摘要:
A process for preparing an optically active 1,4-bridged-cyclohexane carboxylic acid derivatives which are clinically important thromboxane A.sub.2 thromboxane of formula (IV): ##STR1## wherein, R is phenyl or phenyl substituted with hydroxy, lower alkoxy, halogen, or lower alkyl; Y is oxygen, methylene, substituted methylene; m is 0 or 1; n is 0, 1 or 2; q is 3 or 4 with the proviso that when m is 1, n is 0 or 1 from an optically active norbornyl amine derivative.
摘要:
An image communication apparatus includes a communication unit for communicating a procedure signal associated with communication, and image data, a recording unit for ejecting a liquid droplet onto a recording member in accordance with image data received by the communication unit, a recovery unit for performing a predetermined recovery operation of the recording unit, and a control unit for determining according to a type of procedure signal transmitted from a calling side after reception of image data of one page whether or not the recovery operation by the recovery unit is executed.